

To the Honourable

Mr I. Stournaras, Minister of Finance Mr K. Hatzidakis, Minister of Development, Competitiveness, Infrastructure, Transportations and Networks

Cc.: Mr An. Lykourentzos, Minister of Health Mr M. Salmas, Deputy Minister of Health Prof. I. Tountas, President of EOF

Athens, April 18, 2013

Subject: Non-issue on new medicines

Dear Mr Stournaras Dear Mr Chatzidakis

Pharmaceutical industry supports the targets of the government for the rationalising of the pharmaceutical expenditure and has actively participated in this effort since 2009.

Nevertheless, we would like to caution you on the crucial issue concerning the **delay**, for almost 2.5 years, in the licencing and pricing of new medicines, in violation of the Directive (EC) 98/105, according to which the Price Bulletins with the new medicines are issued every ninety (90) days.

It is a fact that the non-issue of new innovative medicines, apart from the serious impact on patients, is the most preventive factor for a smoother course of our companies, while it has, for some time now, a preventive effect in preserving employment, investments and clinical trials in our field.

In addition, marketing of new innovative medicines in the Greek Market, will substantially cover the therapeutic gaps of serious diseases, with medicinal products that have been offered for a long time in the other European citizens.

At this point we would like to point out that the non-issue of new medicines is added to a series of liquidity problems, errors in prices etc. that we face as an industry, which render the planning and development of our pharmaceutical companies, almost impossible.

280 Kifissias Avenue & 3 Agriniou St., 152 32 CHALANDRI, ATHENS TEL. 210 6891101 - FAX 210 6891060



Dear Ministers,

SFEE and the pharmaceutical companies have set as our institutional strategic goal, the support of investments and employment in our country and to that end, we plea that you promptly proceed with all actions required, in order to allow the marketing of new innovative medicines in our country within the following weeks.

Awaiting your prompt positive response.

Yours sincerely

Konstantinos M. Frouzis President Nikos Kefalas Vice President

Konstantinos Panagoulias Vice President Fotis Mangalousis Director General

280 Kifissias Avenue & 3 Agriniou St., 152 32 CHALANDRI, ATHENS TEL. 210 6891101 – FAX 210 6891060

